Revolution Medicines (NASDAQ:RVMD) Rating Increased to Hold at Sanford C. Bernstein

Revolution Medicines (NASDAQ:RVMD) was upgraded by equities research analysts at Sanford C. Bernstein to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Several other equities analysts also recently weighed in on the company. Stifel Nicolaus reaffirmed a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Jefferies Financial Group assumed coverage on Revolution Medicines in a research note on Monday, March 16th. They issued a “buy” rating for the company. Royal Bank Of Canada lifted their price objective on Revolution Medicines to $165.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of Revolution Medicines in a research note on Wednesday, April 22nd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $111.35.

Revolution Medicines Stock Performance

NASDAQ RVMD opened at $151.56 on Thursday. The company has a market cap of $32.22 billion, a P/E ratio of -21.44 and a beta of 1.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The stock has a 50-day moving average of $123.75 and a two-hundred day moving average of $101.21. Revolution Medicines has a 1-year low of $34.00 and a 1-year high of $156.25.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the prior year, the business earned ($1.13) earnings per share. As a group, analysts anticipate that Revolution Medicines will post -7.75 EPS for the current year.

Insider Activity

In related news, insider Stephen Michael Kelsey sold 4,302 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $427,962.96. Following the completion of the sale, the insider owned 295,398 shares in the company, valued at $29,386,193.04. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jack Anders sold 2,753 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the sale, the chief financial officer owned 125,512 shares of the company’s stock, valued at approximately $12,485,933.76. The trade was a 2.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 184,592 shares of company stock valued at $24,499,532 over the last 90 days. Insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors have recently added to or reduced their stakes in the business. Indiana Trust & Investment Management Co purchased a new stake in Revolution Medicines during the fourth quarter worth approximately $32,000. Global Retirement Partners LLC lifted its stake in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the last quarter. Torren Management LLC purchased a new stake in Revolution Medicines during the fourth quarter worth approximately $33,000. Arax Advisory Partners purchased a new stake in Revolution Medicines during the fourth quarter worth approximately $38,000. Finally, Darwin Wealth Management LLC purchased a new stake in Revolution Medicines during the fourth quarter worth approximately $40,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.